Over the past 12 months, 0 insiders at Cerevel Therapeutics Holdings, Inc. filed 0 open-market SEC Form 4 transactions on CERE: 0 purchases worth $0 and 0 sales worth $0. Insiders have been mixed over this period. The most recent filing was on .
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 1, 24 | N Anthony ColesDirector | SELL | 25.0K | $41.18 | $1.0M |
| Jun 3, 24 | N Anthony ColesDirector | SELL | 50.0K | $40.61 | $2.0M |
| May 10, 24 | N Anthony ColesDirector | SELL | 50.0K | $42.10 | $2.1M |
| Apr 1, 24 | N Anthony ColesDirector | SELL | 50.0K | $42.33 | $2.1M |
| Mar 4, 24 | N Anthony ColesDirector | SELL | 50.0K | $41.01 | $2.1M |
| Feb 29, 24 | N Anthony ColesDirector | SELL | 50.0K | $41.16 | $2.1M |
| Feb 7, 24 | N Anthony ColesDirector | SELL | 2.5K | $41.54 | $104K |
| Feb 7, 24 | John RengerChief Scientific Officer | SELL | 2.2K | $41.54 | $90K |
| Jan 2, 24 | N Anthony ColesDirector | SELL | 50.0K | $42.24 | $2.1M |
| Dec 26, 23 | Ramiro SanchezChief Medical Officer | SELL | 10.0K | $42.47 | $425K |
| Dec 22, 23 | Kenneth DipietroChief Human Resources Officer | SELL | 8.0K | $41.45 | $332K |
| Dec 20, 23 | Susan AltschullerChief Financial Officer | SELL | 13.8K | $41.42 | $572K |
| Dec 20, 23 | Scott AkamineChief Legal Officer | SELL | 7.1K | $41.42 | $293K |
| Dec 20, 23 | Mark BodenraderSee Remarks | SELL | 7.9K | $41.42 | $327K |
| Dec 20, 23 | Kenneth DipietroChief Human Resources Officer | SELL | 6.3K | $41.42 | $259K |
| Dec 20, 23 | Ramiro SanchezChief Medical Officer | SELL | 10.2K | $41.42 | $420K |
| Dec 20, 23 | Kathleen TregoningSee Remarks | SELL | 6.3K | $41.42 | $260K |
| Dec 15, 23 | Ramiro SanchezChief Medical Officer | SELL | 7.5K | $41.39 | $310K |
| Dec 7, 23 | Ramiro SanchezChief Medical Officer | SELL | 10.0K | $41.37 | $414K |
| Dec 7, 23 | Scott AkamineChief Legal Officer | SELL | 10.0K | $41.37 | $414K |
| Dec 5, 23 | Scott AkamineChief Legal Officer | SELL | 7.5K | $35.00 | $263K |
| Nov 14, 23 | N Anthony ColesDirector | SELL | 22.8K | $25.13 | $574K |
| Nov 8, 23 | N Anthony ColesDirector | SELL | 100 | $25.16 | $3K |
| Nov 7, 23 | N Anthony ColesDirector | SELL | 27.1K | $25.02 | $677K |
| Nov 3, 23 | N Anthony ColesDirector | SELL | 61.4K | $25.43 | $1.6M |
| Nov 2, 23 | N Anthony ColesDirector | SELL | 38.6K | $25.19 | $972K |
| Nov 1, 23 | Deval L PatrickDirector | SELL | 30.1K | $25.00 | $753K |
| Oct 16, 23 | Bain Capital Investors LlcTenPercentOwner | BUY | 5.48M | $22.81 | $125.0M |
| Oct 16, 23 | Joseph EdelmanDirector | BUY | 876.8K | $22.81 | $20.0M |
| Oct 16, 23 | Christopher R GordonDirector,TenPercentOwner | BUY | 5.48M | $22.81 | $125.0M |
| Oct 16, 23 | Adam KoppelDirector,TenPercentOwner | BUY | 5.48M | $22.81 | $125.0M |
| Sep 7, 23 | N Anthony ColesDirector | SELL | 50.0K | $24.07 | $1.2M |
| Aug 4, 23 | Paul D. BurgessSee Remarks | BUY | 21.9K | $22.93 | $502K |
| Aug 3, 23 | Ronald C Renaud JrPresident & CEO | BUY | 83.9K | $23.96 | $2.0M |
| Jul 11, 23 | N Anthony ColesDirector | SELL | 50.0K | $30.03 | $1.5M |
| Jun 15, 23 | Marijn E DekkersDirector | SELL | 200.0K | $34.43 | $6.9M |
| Jun 2, 23 | Mark BodenraderSee Remarks | SELL | 1.9K | $32.95 | $62K |
| Jun 1, 23 | N Anthony ColesCEO and Chairperson | SELL | 50.0K | $32.60 | $1.6M |
| May 4, 23 | N Anthony ColesCEO and Chairperson | SELL | 37.6K | $32.93 | $1.2M |
| Apr 11, 23 | N Anthony ColesCEO and Chairperson | SELL | 50.0K | $25.06 | $1.3M |
| Mar 3, 23 | N Anthony ColesCEO and Chairperson | SELL | 3.0K | $27.19 | $82K |
| Mar 2, 23 | N Anthony ColesCEO and Chairperson | SELL | 47.0K | $27.11 | $1.3M |
| Feb 7, 23 | N Anthony ColesCEO and Chairperson | SELL | 42.1K | $33.57 | $1.4M |
| Jan 5, 23 | N Anthony ColesCEO and Chairperson | SELL | 49.5K | $30.73 | $1.5M |
| Dec 9, 22 | N Anthony ColesCEO and Chairperson | SELL | 44.9K | $27.09 | $1.2M |
| Nov 1, 22 | John RengerChief Scientific Officer | SELL | 25.0K | $30.00 | $750K |
| Oct 4, 22 | John RengerChief Scientific Officer | SELL | 25.0K | $30.00 | $750K |
| Sep 12, 22 | Deval L PatrickDirector | SELL | 47.7K | $30.78 | $1.5M |
| Sep 8, 22 | Abraham CeesayPresident | SELL | 19.2K | $32.50 | $624K |
| Aug 22, 22 | Abraham CeesayPresident | SELL | 9.6K | $32.50 | $312K |
Over the past 12 months, insiders at Cerevel Therapeutics Holdings, Inc. filed 0 open-market purchases worth $0 and 0 sales worth $0 on CERE, which makes them mixed over the period. The most recent Form 4 was filed on .
The largest recent open-market CERE insider purchase in our data was $125.0M by Bain Capital Investors Llc, TenPercentOwner, filed on Oct 16, 23.
0 different insiders at Cerevel Therapeutics Holdings, Inc. filed open-market SEC Form 4 transactions on CERE over the last 12 months.
InsiderTape plots every CERE insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Cerevel Therapeutics Holdings, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →